Amneal Pharmaceuticals (NASDAQ:AMRX) & Collegium Pharmaceutical (NASDAQ:COLL) Head to Head Survey

Amneal Pharmaceuticals (NASDAQ:AMRX – Get Free Report) and Collegium Pharmaceutical (NASDAQ:COLL – Get Free Report) are both medical companies, but which is the better stock? We will contrast the two companies based on the strength of their risk, dividends, valuation, institutional ownership, profitability, earnings and analyst recommendations.

Valuation and Earnings

This table compares Amneal Pharmaceuticals and Collegium Pharmaceutical”s revenue, earnings per share (EPS) and valuation.

Amneal Pharmaceuticals has higher revenue and earnings than Collegium Pharmaceutical. Collegium Pharmaceutical is trading at a lower price-to-earnings ratio than Amneal Pharmaceuticals, indicating that it is currently the more affordable of the two stocks.

Profitability

This table compares Amneal Pharmaceuticals and Collegium Pharmaceutical’s net margins, return on equity and return on assets.

Insider and Institutional Ownership

31.8% of Amneal Pharmaceuticals shares are owned by institutional investors. 17.3% of Amneal Pharmaceuticals shares are owned by insiders. Comparatively, 1.9% of Collegium Pharmaceutical shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock will outperform the market over the long term.

Analyst Ratings

This is a breakdown of recent ratings and recommmendations for Amneal Pharmaceuticals and Collegium Pharmaceutical, as provided by MarketBeat.

Amneal Pharmaceuticals currently has a consensus target price of $15.00, indicating a potential upside of 18.97%. Collegium Pharmaceutical has a consensus target price of $57.50, indicating a potential upside of 63.58%. Given Collegium Pharmaceutical’s higher possible upside, analysts plainly believe Collegium Pharmaceutical is more favorable than Amneal Pharmaceuticals.

Risk & Volatility

Amneal Pharmaceuticals has a beta of 1.32, meaning that its stock price is 32% more volatile than the S&P 500. Comparatively, Collegium Pharmaceutical has a beta of 0.76, meaning that its stock price is 24% less volatile than the S&P 500.

Summary

Amneal Pharmaceuticals beats Collegium Pharmaceutical on 8 of the 14 factors compared between the two stocks.

About Amneal Pharmaceuticals

(Get Free Report)

Amneal Pharmaceuticals, Inc., together with its subsidiaries, develops, manufactures, markets, and distributes generics, injectables, biosimilars, and specialty branded pharmaceutical products worldwide. The company operates through three segments: Generics, Specialty, and AvKARE. The Generics segment offers immediate and extended release oral solid, powder, liquid, sterile injectable, nasal spray, inhalation and respiratory, biosimilar, ophthalmic, film, transdermal patch, and topical products. The Specialty segment develops, promotes, sells, and distributes pharmaceutical products with focus on central nervous system disorders, including Parkinson's disease, and endocrine disorders. This segment also provides Rytary, an oral capsule formulation of carbidopa-levodopa to treat Parkinson's disease, post-encephalitic parkinsonism, and parkinsonism; Unithroid for the treatment of hypothyroidism; and IPX203, a pipeline product for Parkinson's disease. The AvKARE segment offers pharmaceuticals, medical and surgical products, and services primarily to governmental agencies, the Department of Defense, and the Department of Veterans Affairs. This segment also distributes bottle and unit dose pharmaceuticals under the AvKARE and AvPAK names; and packages and distributes pharmaceuticals and vitamins to its retail and institutional customers. It sells its products through wholesalers, distributors, hospitals, chain pharmacies, and individual pharmacies. The company was formerly known as Atlas Holdings, Inc. and changed its name to Amneal Pharmaceuticals, Inc. in 2018. Amneal Pharmaceuticals, Inc. was founded in 2002 and is headquartered in Bridgewater, New Jersey.

About Collegium Pharmaceutical

(Get Free Report)

Collegium Pharmaceutical, Inc., a specialty pharmaceutical company, engages in the development and commercialization of medicines for pain management. Its portfolio includes Xtampza ER, an abuse-deterrent, extended-release, and oral formulation of oxycodone for the management of pain severe enough to require daily, around-the-clock, long-term opioid treatment; Nucynta ER and Nucynta IR, which are extended-release and immediate-release formulations of tapentadol, indicated for the management of acute, severe, and persistent pain; Belbuca, a buccal film that contains buprenorphine; and Symproic, an oral formulation of naldemedine for the treatment of opioid-induced constipation in adult patients with chronic non-cancer pain. The company was formerly known as Collegium Pharmaceuticals, Inc. and changed its name to Collegium Pharmaceutical, Inc. in October 2003. Collegium Pharmaceutical, Inc. was incorporated in 2002 and is headquartered in Stoughton, Massachusetts.